Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rBV A/B for BabyBIG Production in Immune Volunteers
NCT03676634Phase 2Completed
- Sponsor
- California Department of Public Health
- Start
- Mar 2019
- Primary completion
- Apr 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant botulinum vaccine A/B in botulism, sponsored by California Department of Public Health. Primary endpoint: Proportion of Subjects Achieving Greater Than 3- or 4-Fold Increases in Neutralizing Antibody Concentration at 4 weeks. Started Mar 2019; status: completed.
02
Drugs
recombinant botulinum vaccine A/B
03
Conditions
botulism
Beyond the preview
Go deeper on NCT03676634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03676634.